Screener
Axsome Therapeutics AXSM Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204274
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Net cash used in operating activities | (20,700) | (43,375) |
| Cash flows from investing activities | ||
| Purchases of equipment | (121) | (338) |
| Net cash used in investing activities | (121) | (338) |
| Cash flows from financing activities | ||
| Proceeds from draw down of debt | 70,000 | — |
| Repayment of debt | (70,000) | — |
| Payments on principal portion of finance lease obligation | (672) | (401) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Axsome Therapeutics's investing cash flow?
- Axsome Therapeutics (AXSM) reported investing cash flow of -$121K in Q1 2026.
- How has Axsome Therapeutics's investing cash flow changed year-over-year?
- Axsome Therapeutics's investing cash flow increased by 64.2% year-over-year, from -$338K to -$121K.
- What is the long-term trend for Axsome Therapeutics's investing cash flow?
- Over 4 years (2021 to 2025), Axsome Therapeutics's investing cash flow has grown at a 11.7% compound annual growth rate (CAGR), from -$308K to -$480K.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Axsome Therapeutics's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude